Drug Trial Radar · NCT03634852
A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Oct 1, 2016
Primary completion
Feb 1, 2018
Study completion Feb 1, 2018
Sponsor
- Lead sponsor
- Suzan A RattanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Al-Kindy College of Medicine
- First posted
- Aug 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 38 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post cataract surgery bacterial endophthalmitis is a rare but the most devastating complication with a poor visual outcome. The preferred pattern of chemoprophylaxis varied world widely. The use of preoperative povidone iodine is universal. Most European surgeons prefer the use of Intracameral (IC) antibiotics whereas topical fluoroquinolone that prescribed perioperatively is the most common pattern in the United state(US). The current study aimed to evaluate the effectivity and safety of a combination of diluted IC Moxifloxacin and subconjunctival (SC) Triamcinolone acetonide as prophylaxis of bacterial endophthalmitis and postoperative inflammation in five hundred phacoemulsification surgeries and compare its results with the same number of patients treated by topical Moxifloxacin hydrochloride and Dexamethasone eye drops when given four times a day for 1month postoperatively.
Conditions
- Endophthalmitis Postoperative
Interventions
Moxifloxacin hydrochloride 0.5% eye dropsDrug
were prescribed four times a day for 1-month postoperatively
Dexamethasone 0.1% eye dropsDrug
were prescribed four times a day for 1-month postoperatively
Intracameral Moxifloxacin 0.1%Drug
Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq. Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient.
Subconjunctival Triamcinolone acetonide 4 mg /0.4 mlDrug
Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country. The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Bacterial endophthalmitis in 1000 phacoemulsification surgeriesTime frame: The duration of follow up for each patient was a 3 months postoperatively.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.